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Spironolactone-Induced Inhibition of Aldosterone 
Biosynthesis in Primary Aldosteronism : 
Morphological and Functional Studies 
J. W. Conn and D. L. Hinerman 
Twenty-five patients harboring aldo- 
sterone-producing adenomas were treated 
with spironolactone for 2-170 days 
immediately preoperatively. In the early 
period of administration of the drug (up 
to 27 days), plasma and urinary aldo- 
sterone decreased sharply while plasma 
renin activity (PRA) and serum potassium 
were rising. During this period of time, 
spironolactone bodies (SB), which form 
exclusively in cells actively producing 
aldosterone, were forming rapidly in the 
tumor cells but not in the inactive glomer- 
ulosa cells proper. The SB appear to be a 
morphological expression of a block in 
aldosterone biosynthesis. Since SB do not 
occur in normal fasciculata cells, which, 
like glomerulosa cells, also synthesize 
corticosterone, it is concluded that spirono- 
lactone inhibition of aldosterone biosyn- 
thesis occurs between corticosterone and 
aldosterone. Recent studies in vitro by 
others have suggested that the inhibition 
occurs at the corticosterone-methyl oxidase 
step, I (Ulick’s nomenclature). The great 
diuresis of sodium and retention of po- 
tassium resulting from continued ad- 
ministration of the drug sharply activates 
aldosterone stimulatory factors. Aldo- 
sterone production may return to baseline 
levels in several weeks but it is inap- 
propriately low in relation to the levels of 
PRA and serum potassium. With the fur- 
ther passage of time (average 4-6 wk), 
aldosterone production may increase 
50%-100% above baseline levels, sug- 
gesting that the block has disappeared or 
is receding. At this time SB are diminish- 
ing in number and by 170 days of the drug 
they have virtually disappeared. We have 
hypothesized, among other possibilities, 
that recovery of the ability to convert 
corticosterone to aldosterone occurs by 
virtue of a mechanism activated by sodium 
deficiency, independent of angiotensin, 
which stimulates step 1 of the corticos- 
terone-methyl oxidase system. As the 
block in the final step(s) of the biosyn- 
thetic pathway recedes, the existing 
elevated levels of angiotensin become 
much more effective in stimulating the 
production of aldosterone. 
S PIRONOLACTONE antagonizes the sodium-retaining effects of aldo- sterone by competing with the hormone at its cellular receptor sites (kid- 
ney, sweat glands, lacrimal glands, salivary glands, and intestine). From a 
physiologic point of view, its major influence is via the kidney, where it inhibits 
aldosterone-mediated sodium reabsorption and aldosterone-mediated potas- 
sium secretion. The sodium diuresis thus induced results in a contraction of 
intravascular volume and stimulation of renin release. This effect should result 
in increased production of aldosterone. Stimulation of the renin-angiotensin 
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aldosterone system is expected from any agent which produces a loss of sodium 
and water from the body. However, we have previously reported in abstract 
form’ that spironolactone, in addition to being a peripheral aldosterone antag- 
onist. has a direct inhibiting effect on aldosterone production in the ceils of 
aldosterone-producing adenomas. 
Five years after the 17-spirolactone steroids and spironolactone came into 
clinical use, Janigan.2 studying autopsy material, described the occurrence of 
eosinophilic, laminated bodies within the cytoplasm of the cells of the adrenal 
glomerulosa zone in patients who, during life, had received these compounds 
for the management of various forms of edema. People with similar disorders, 
treated with other forms of diuretic therapy, failed to exhibit such bodies in 
their adrenal glands. Six years later these observations were confirmed and 
extended by Jenis and Hertzog3 and Davis and Medline4 with the aid of elec- 
tron microscopy. These bodies consist of whorls of concentrically arranged 
cytoplasmic reticulum containing a central core of lipid material. Within the 
cell they are 2-20 p in diameter and they are found exclusively in the aldoste- 
rone-producing cells (glomerulosa cells) of the adrenal cortex. Careful search 
by Jenis and Hertzog3 indicated that “spironolactone bodies” (SB) were not 
found in any other region of the adrenal gland or in any other organ of the 
body. All of the foregoing studies were carried out on postmortem material. 
In a preliminary communication we’ reported studies concerning the forma- 
tion and regression of SB in living people. We had observed these bodies in 
adrenal tissue surgically removed from patients with primary aldosteronism 
who had received spironolactone preoperatively. We proceeded with further 
studies in an attempt to relate the morphological changes to concurrent physio- 
logic changes in aldosterone production and plasma renin activity (PRA). 
From such data we concluded that spironolactone exerts a direct effect upon 
aldosterone-producing cells, inhibiting the production and/or release of aldo- 
sterone, and that the SB are a morphological reflection of a block in aldosterone 
biosynthesis. We also reported that in primary aldosteronism due to adenoma 
the SB were confined to the tumor and were absent in the glomerulosa zone 
of the adrenal cortex proper, indicating that they form only in cells that are 
actively producing aldosterone. It was observed, too, that the number of 
bodies formed under the influence of spironolactone was related to the duration 
of spironolactone administration rather than to the dose administered (1% 
400 mg/day). Finally, to be certain that these “bodies” were induced by 
spironolactone and were not the result of overactivity of aldosterone-producing 
cells, we reviewed adenoma sections from 83 of our cases of primary aldo- 
steronism that had never received spironolactone. In no instance was anything 
resembling an SB encountered. 
The present report provides new details regarding the blocking action of 
spironolactone upon aldosterone production in patients harboring an aldo- 
sterone-producing adenoma and modifies some of our earlier interpretations. 
MATERIALS AND METHODS 
Twenty-iive patients from whom aldosterone-producing adenomas were subsequently removed 
have been studied. Preoperatively all exhibited the diagnostic combination of excessive excretion 
of aldosterone, together with subnormal levels of PRA.’ Twenty-three were treated with spirono- 
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lactone (150-400 mg/day) up to the time of operation (the last dose was given at COO p.m. the 
evening before) for 22170 days. Two patients received the drug for 81 and 86 days, respectively, 
but it was discontinued I8 and 24 days, respectively, before operation. At surgery, 24 patients 
were found to have a solitary adenoma and I patient had two adenomas in one adrenal gland. 
Sections of the adrenal tissue removed at operation were stained with hemotoxyhn and eosin. 
SB body counts were recorded by averaging the number of bodies counted in five random high- 
power tields at a magnification of x400. Electron microscopic study of the intracytoplasmic 
bodies was also carried out, 
All specimens for determinations of urinary and plasma aldosterone and PRA were collected 
after the patient had been ingesting, for at least 3 days, a diet containing 120 mEq of sodium and 
approximately 70 mEq of potassium per day. Specimens for plasma aldosterone and PRA deter- 
minations were drawn at 8:00 a.m.. with the patient still recumbent, after an overnight sleeping 
period. Aldosterone and PRA were each measured by radioimmunoassay methods previously 
described by laboratory.6,7 
RESULTS 
Morphological Studies 
Figure I is an electron micrograph of a typical SB within the cytoplasm of an 
adenoma cell. It demonstrates the whorling of tightly packed, concentric, 
agranular membranes that is characteristic of these bodies. Having observed 
Fig. 1. Electron micrograph of a portion of an adenoma cell showing extensive whorling of cyto- 
membranes characteristic of a spironolactone body. The cell contains abundant smooth endoplasmic 
reticulum and mitochondria. The broad flattened mitochondrial christae are characteristic of 
glomerulosa cells. x 23,000. 
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Fig. 2. Spironolactone bodies in a section from an aldorterone-producing adenoma. Pink 
stained, laminated, intracytoplasmic bodies ore seen within a white halo. x 750. 
Fig. 3. Broad distribution of spironolactone bodies as seen with lower magnification. x400. 
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the electron micrograph, one can appreciate better the appearance of SB as 
seen under the light microscope. 
Figure 2 is a section from an aldosterone-producing adenoma under the light 
microscope. The patient had received spironolactone, 400 mg/day, for 25 days. 
The bodies stain pink with eosin and are seen within a white halo. The coiled 
watch-spring-like structures are SB. No such bodies were observed in the 
glomerulosa cells of the nontumorous portion of the gland. 
Figure 3 demonstrates a section from the same tumor at lower power and 
shows the broad distribution of the bodies which are easily counted. 
Figure 4 shows the “life cycle” of the SB as derived from counts in the 
adenomas of 23 of the 25 patients with proven primary aldosteronism. The 
average daily dose for each patient is recorded in parentheses. The vertical axis 
indicates the SB count. The horizontal axis shows the duration of spirono- 
la&one administration up to the time of operation. It will be observed that the 
peak counts occur between 40 and 60 days, with a gradual and highly significant 
increase between 4 and 50 days (r = 0.910, p < 0.0001). Then there is a slow 
and significant decrease from 50 to 170 days (r = 0.887, p < 0.005). Note that 
the counts follow the regression lines in relation to time, regardless of the 
dosage (150-400 mg/day). Bodies are not seen until the patient has received 
the drug for 3-4 days. Note, too, that at 100 and 110 days there are two addi- 
tional adenoma cases that were operated upon but showed no SB. In these two 
patients the drug had been discontinued 18 and 24 days before operation. These 
two values were, of course, not computed in the regression lines produced by 
0-N q 23 Primary Aldasteranism (Tumor) 
4-N = 2 Primary Aldasteronism (Turnar) Not Computed 
+I Drug Stopped I8 Days Preap. 
41 Drug Stopped 24 Days Preop. 
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Fig. 4. “life cycle” of spironolactone bodies based upon spironolactone body counts and the 
duration of therapy up to the time of operation. 
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the other 23 cases, but they provided information regarding the rates of forma- 
tion and disappearance of SB at 100 days of administration of the drug. 
Physiologic Studies 
To study the renin-aldosterone system as SB were being formed rapidly, we 
elected to observe this system in detail during the first 20 days of spironolactone 
administration, with removal of the adenoma immediately at the end of the 
short course of the drug. In less detailed studies, in nine patients with aldo- 
sterone-producing adenomas we had observed a sharp decrease in aldosterone 
excretion for as long as 27 days after the beginning of treatment. Those results 
will be presented below. The three patients chosen for detailed study received 
spironolactone for 10, 11, and 20 days, respectively. 
Figure 5 shows the results obtained in a patient who received 400 mg daily 
for 10 days preceding operation. By the sixth day, aldosterone excretion had 
fallen to 5040 of the mean baseline value. It then fluctuated at relatively low 
values for 4 days and again reached 509; of the mean baseline value on the day 
before operation. By the eighth day of spironolactone, plasma aldosterone had 
fallen from 18.9 and 23.6 ng/lOO ml to 9.6 ng/lOO ml. PRA rose slowly from 
very low levels into the normal range by the day before operation. However, 
despite this rise in PRA, plus a rise of serum potassium from 3.0 to 4.6 mEq/ 
liter, aldosterone excretion was still 50”:, below baseline. Upon removal of the 
adenoma and of spironolactone therapy, aldosterone excretion remained in the 
g 35r 3.5r 
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Fig. 5. Effect of spironolactone (for 10 days preoperatively) on plasma and urinary aldo- 
sterone, plasma renin activity, and serum potassium in a case of aldosterone-producing ade- 
noma. 
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low normal range for several days (suggesting mild activation of the “normal” 
glomerulosa cells), following which the renin-aldosterone system returned to a 
suppressed state. Table 1 presents additional data on electrolyte excretion and 
weight changes in the course of this study. During spironolactone therapy 
there was a marked sodium diuresis and potassium retention with a rapid rise 
in serum potassium and a loss of 4.5 kg of body weight, but plasma and urinary 
aldosterone, rather than increasing, had decreased. 
Figure 6 shows a similar series of events during an 1 l-day period of spirono- 
lactone administration (400 mg/day). Urinary and plasma aldosterone fell as 
PRA rose from 0.5 to 1.0 ng/ml/hr and serum potassium rose from 2.8 to 4.3 
mEq/liter. Aldosterone fell from 53 to 27 ng/lOO ml. Following removal of the 
adenoma, the normal glomerulosa cells showed no evidence of aldosterone- 
producing activity, even though PRA had risen from 0.5 to 2.5 ng/ml/hr and 
serum potassium had risen from 2.8 to 4.8 mEq/liter. 
Figure 7 shows the results obtained in a patient given spironolactone for 20 
days before operation. This was a mild case, as can be seen from the preopera- 
tive levels of serum potassium. Because it was mild, it telescoped in a short 
period of time various phenomena that usually require much more time to 
occur. Upon administration of spironolactone, there was a transient, initial 
Table 1. Primary Aldosteronism: Preoperative Treatment 
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235 69 0.06 
156 33 0.07 
140 36 0.10 
121 42 0.14 
138 48 0.24 
144 61 0.36 
142 58 0.75 
132 61 0.73 
147 66 0.92 
96 47 1.20 
1st 72.3 142 5.1 126 68 
14 70.9 137 4.5 119 87 
15 71.0 129 4.5 60 58 
16 70.3 138 4.2 52 54 
17 70.3 138 4.6 58 57 
18 70.1 143 4.5 63 52 
19 70.0 142 4.6 74 57 
20 70.9 144 4.4 113 67 
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Fig. 6. Effect of spironolactone (for 11 days preoperatively) on plasma and urinary aldosterone, 
plasma renin activity, and serum potassium in a case of aldosterone-producing adenoma. 
decrease in aldosterone excretion. By the seventh day of spironolactone ad- 
ministration (day ll), with a sharp rise in PRA, aldosterone excretion came 
back to baseline values. The obvious blocking action of spironolactone on 
aldosterone production seen in the other two cases is much less clear in this 
one. Nevertheless, the inhibiting effect on aldosterone production is still evi- 
dent in that aldosterone excretion was at the prespironolactone level, while 
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Fig. 7. Effect of spironolactone (for 20 days preoperatively) on aldosterone excretion, plasma 
renin activity, and serum potassium in CI case of aldosterone-producing adenoma. 
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Case No. No 120 mEq/day lo-14days 6wk 
1 0.1 0.4 0.6 
2 0.1 1.9 
3 0.1 9.6 
4 0.2 0.6 9.9 
5 0.4 27.0 
6 0.5 0.5 0.7 
7 0.5 1.2 
B 0.6 0.1 
9 0.8 6.8 
10 1 .o 14.9 
Normal 7.7 i 1 .O (SEM). 
On day 15 and beyond, a very large increase in PRA occurred (note the break 
in the scale) and aldosterone excretion went to twice its baseline value. Under 
the latter circumstances it would be difficult to invoke a continuing spironolac- 
tone block on aldosterone biosynthesis. The same phenomenon, however, oc- 
curs in most spironolactone-treated adenoma cases, but it is usually seen after 
5 or 6 wk of therapy.8 Table 2 indicates the great variability among patients 
in the time required to increase PRA by means of spironolactone therapy. In 
some (cases 1 and 6) it is still severely suppressed after 6 wk. In others (cases 
9 and 10) it is normalized in lo-14 days, as it was in the present case (Fig. 7). 
Following removal of the adenoma from this patient there was evidence of 
transient aldosterone production by the normal glomerulosa cells for a short 
time, after which they again became suppressed. They appear to have assumed 
some function before the operation because a few SB were seen in the glomeru- 
losa cells proper (an unusual occurrence), as well as in the adenoma cells. 
Figure 8 summarizes the early changes (l-27 days) in aldosterone excretion 
induced by spironolactone in the 12 cases in which these data were available. 
The open circles represent the day before operation and the duration of spi- 
ronolactone administration preoperatively. The solid circles represent aldo- 
sterone determinations done while the patients were on spironolactone before 
operation. In all 12 cases there was a decrease in aldosterone excretion of 
25”,~~83”,0. The solid circle at 27 days of spironolactone therapy represents a 
decrease from baseline of 76”,,,. However, by the time of operation at 170 days, 
aldosterone excretion was loo”,, above baseline. The line labeled J.M. repre- 
sents the patient described in detail (Fig. 7) who telescoped the whole phe- 
nomenon into a short period of time. For comparison, the solid square averages 
the results obtained in 6 adenoma cases treated with spironolactone for 35 days8 
and the solid triangle represents the mean of 27 patients with essential hyper- 
tension, treated for 70 days.’ 
DISCUSSION 
From a study of 25 patients with primary aldosteronism, an attempt has 
been made to correlate the effects of spironolactone upon function and struc- 
ture of aldosterone-secreting adenoma cells. At the beginning of administration 
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Fig. 8. Effect of spironolactone (for 2-170 days preoperatively) on aldosterone excretion in 
12 patients with aldosterone-producing adenoma. 
of the drug, two events occur simultaneously: (1) a sharp decrease in plasma 
and urinary aldosterone, and (2) the appearance in the tumor cells of the intra- 
cytoplasmic, laminated, eosinophilic bodies (spironolactone bodies). 
Patients with aldosterone-producing adenomas are ideal subjects in which to 
demonstrate the blocking action of spironolactone on aldosterone biosynthesis 
because, at the beginning of administration of the drug, the major known 
stimuli for aldosterone production (angiotensin”, serum potassium, and re- 
duced serum sodium) are suppressed. The normal glomerulosa cells are produc- 
ing little, if any, aldosterone. The adenoma is secreting aldosterone autono- 
mously except, perhaps, for the circadian variation induced in some tumors 
by the normal fluctuations of ACTH release.“,” Under these conditions one ob- 
serves the spironolactone blockade of aldosterone production in the adenoma 
itself. This is the beginning of phase I of a two-phase overall reaction to spi- 
ronolactone in patients with primary aldosteronism. 
Phase I: Inhibition of Aldosterone Biosynthesis 
Phase I is usually demonstrable for 4-6 wk, but, in unusual cases, it may be 
observed for only 1 wk or, occasionally, for several months. In the average 
case, aldosterone production diminishes significantly as SB are being formed 
rapidly in the tumor cells. During this time SB are not forming in the glomeru- 
losa cells proper. Since the latter cells are not producing aldosterone, we have 
concluded that (1) SB are formed only in cells that are actively producing aldo- 
sterone, and (2) the SB are a morphologic reflection of a block in aldosterone 
biosynthesis within aldosterone-producing cells. 
In addition, these morphologic observations allow us to place the site of the 
block beyond the formation of corticosterone in one or both of the final steps 
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of the aldosterone biosynthetic pathway. SB form only in aldosterone-produc- 
ing cells. They do not occur in normal cells of the fasciculata zone. It has been 
well established that the biosynthesis of corticosterone proceeds similarly in 
both the glomerulosa cells and the fasciculata cells. If the SB are regarded as a 
morphological expression of a block in aldosterone biosynthesis, this inhibitory 
effect is exerted within the glomerulosa cell, where the final two steps of aldo- 
sterone biosynthesis occur. Until recently these two steps had been considered 
to consist of 18-hydroxylation of corticosterone to form the intermediary 
compound, 18-hydroxycorticosterone, followed by dehydrogenation of that 
compound to produce aldosterone. Ulicki2 has recently suggested a new con- 
cept involving “corticosterone-methyl oxidase” in a two-step reaction in 
which 18-hydroxycorticosterone is formed as a side reaction in step I and 
aldosterone is produced in a second methyl oxidase reaction in step II. In fur- 
ther discussion we employ this new nomenclature. 
Morphologically, our studies appear to localize the inhibiting effect of 
spironolactone to one or both of the final two steps of aldosterone biosyn- 
thesis. We have no studies of precursor compounds with which to identify more 
precisely the site of the inhibitory effect. However, since our initial report,’ 
others have observed that spironolactone inhibits aldosterone production in 
man and in animals.“-” The in vitro studies of Cheng et a1.15 suggest that step I 
of the corticosterone-methyl oxidase reaction is inhibited by spironolactone. 
That group studied mitochondria from an aldosterone-producing adenoma, 
and also from glomerulosa cells of beef adrenal glands. In both instances, spi- 
ronolactone inhibited the synthesis of both 18-hydroxycorticosterone and aldo- 
sterone. 
Phase II: “Escape” From the Inhibitory EJect of Spironolactone 
on AIdosterone Biosynthesis 
Upon continued administration of spironolactone for about 1 mo (in the 
average case of primary aldosteronism), aldosterone production rises to base- 
line values and frequently considerably above. Formation of SB ceases and 
their numbers gradually diminish to almost zero by 170 days. It is to be recalled 
that in phase I aldosterone production was very resistant to stimulation by the 
elevations of PRA and serum potassium induced by the renal effects of spi- 
ronolactone. It is of interest, in this connection, that Kremer et a1.,18 studying 
a group of patients with aldosterone-producing tumors before and after 4 wk of 
spironolactone therapy, noted great rises in renin, but only erratic increases or 
none in aldosterone production. In those studies, the early decreases in aldo- 
sterone production, which we have reported above, were not observed because 
the second determinations were carried out too late. The fact, however, that 
aldosterone production, after 4 wk of spironolactone, was not increased or 
was only erratically higher than the prespironolactone values, while renin 
was considerably elevated, suggests that spironolactone was still impeding aldo- 
sterone biosynthesis. 
Occasionally one encounters a case of aldosterone-producing adenoma in 
which it is clear that spironolactone has inhibited aldosterone production for 
unusually long periods of time. The case reported by Mantero et aLI9 exhibited 
a decrease in urinary aldosterone from 48- 53 pg/day to 1 l-20 pg/day after 
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4 wk of spironolactone therapy; in one of our cases (Fig. 8), aldosterone excre- 
tion was similarly decreased by 76”; after 27 days of therapy. Sundsfjord et al.16 
have reported a case in which high values for plasma and urinary aldosterone 
fell to normal values and remained there for 4 mo under continuous therapy 
with spironolactone, even though PRA and serum potassium had long been 
normal or above normal. Nevertheless, most adenoma cases respond to long- 
term spironolactone therapy with a brisk increase of aldosterone production, 
which may be 507,- 1009, higher than the prespironolactone level of aldosterone 
production (Fig. 8). Spark et aL8 studied six patients with aldosteroneeproducing 
adenomas after they had received 400 mg/day of spironolactone for 35 days 
and found that the daily excretion of aldosterone was 40”,,~50”,, higher than 
the prespironolactone level. PRA levels were, of course, already elevated, but a 
IO-min infusion of angiotensin” gave evidence of extreme sensitivity of the 
tumor to acute elevations of angiotensin”. The adrenal venous effluent from 
the tumor side more than doubled its aldosterone concentration after 10 min 
of subpressor doses of angiotensin”, while there was essentially no response 
from the contralateral side. Of great interest in those studies is the finding that 
18-hydroxycorticosterone concentration on the tumor side more than tripled 
by the end of the infusion. It thus appears that by 5 or 6 wk of continuous ad- 
ministration of large doses of spironolactone, the tumor cells “escape” from 
their former state of drug-induced inhibition of aldosterone biosynthesis, and 
when this occurs both aldosterone and 18-hydroxycorticosterone are being pro- 
duced in excessive amounts. 
We are interested in the possible mechanisms by which a block in the con- 
version of corticosterone to aldosterone seems to disappear after 446 wk of 
administration of spironolactone. In the average patient with an aldosterone- 
producing adenoma, by this time, a large amount of sodium has been lost from 
the body by virtue of the peripheral effects of the drug. Blood pressure has re- 
turned to normal and serum electrolyte values have come into the normal 
range. There is, in fact, a sufficient sodium deficit such that renin values are 
quite high. The easiest explanation for the escape phase is that when plasma 
angiotensin” concentration rises to elevated levels for a sufficiently long period 
of time, the adenoma cells finally respond to it. Furthermore, there is clear 
evidence that sodium deficit increases sensitivity to angiotensin” of aldosterone- 
producing cells. *O However, the major effect of angiotensin” on aldosterone 
biosynthesis occurs in an early step of the biosynthetic pathway*’ and it would 
not be expected to alleviate a block in the final step(s). There is no convincing 
evidence that angiotensin” can increase the in vivo rate of conversion of corti- 
costerone to aldosterone.22 However, it has been demonstrated that this conver- 
sion is clearly enhanced by sodium privation.23m’8 Thus, a second, and some- 
what more attractive postulate can be proposed, namely, that the state of 
sodium deficiency activates a mechanism which increases conversion of cortico- 
sterone to aldosterone; and that when this has been accomplished, the elevated 
levels of angiotensin ” become much more effective in stimulating aldosterone 
production. Indeed, this is probably the explanation for the increasing effective- 
ness of angiotensin” as a stimulus for aldosterone production with increasing 
degrees of sodium deficit in normal man.20 
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It should be recalled that patients with primary aldosteronism not treated 
with spironolactone do not augment aldosterone production upon infusion 
of angiotensin”.29 Thus, in the presence of sodium deficiency, both the early 
(angiotensin”) and late steps of aldosterone biosynthesis would be stimulated to 
increased activity. Teleologically, this would be important in maximizing aldo- 
sterone production for conservation of body sodium. The implication is that 
sodium deficit, independent of its hyperreninemic effect, activates a mechanism 
which increases the activity of the corticosterone-methyl oxidase system. Simi- 
lar conclusions have been suggested in the past 27~30,31 as the result of studies of a 
different nature than those reported here. 
In the case of neoplastic aldosterone-producing cells, the following points 
are relevant. These cells are producing aldosterone in large amounts in the 
presence of hypokalemia, hypernatremia, hyporeninemia, and normal amounts 
of ACTH. Presumably, the “sodium-deficit factor” is also suppressed since, 
in primary aldosteronism, there is an overabundance of sodium in the body. 
Thus, aldosterone biosynthetic enzymatic activity is proceeding in high gear 
despite suppression of all known stimulative factors. In fact, it has been re- 
ported by two groups32,33 that 1%hydroxylase activity (corticosteroneemethyl 
oxidase activity, step I) is considerably increased in aldosterone-producing 
adenoma tissue. Partial or complete interference with the activity of this 
enzyme by spironolactone would appear to account for the early inhibition of 
aldosterone biosynthesis in tumor cases. After sufficient sodium deficit has 
occurred, induction of increased activity of the same enzyme by the “sodium- 
deficit factor” in the presence of hyperreninemia may account for recovery in 
phase II. In the rare instances in which phase I persists 4-6 mo,16 this enzyme 
system within the tumor cells may have been much more severely injured. 
A third possibility to explain recovery of aldosterone production by the tumor 
cells is that intracellular potassium may have risen substantially as the result 
of potassium-retaining effects of the drug. However, in the tumor cells this 
possibility seems unlikely since before the administration of spironolactone 
these same cells were producing an abundance of aldosterone in the presence of 
severe hypokalemia and a presumed deficit of intracellular potassium. 
In conclusion, spironolactone exerts an inhibiting influence on aldosterone 
biosynthesis in aldosterone-producing adenoma cells. The development of SB 
in these cells, and not in fasciculata ceils, appears to place the site of inhibition 
after the formation of corticosterone and most likely at step I of the corticos- 
terone-methyl oxidase reaction of Ulick.12 With time and continued adminis- 
tration of spironolactone, the inhibitory effect upon aldosterone production by 
the adenoma lessens or disappears. SB also diminish or disappear. Several 
possibilities have been considered to explain the recovery phase of this two- 
phase phenomenon. 
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